These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

617 related articles for article (PubMed ID: 29146734)

  • 1. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy.
    Wang M; Yao LC; Cheng M; Cai D; Martinek J; Pan CX; Shi W; Ma AH; De Vere White RW; Airhart S; Liu ET; Banchereau J; Brehm MA; Greiner DL; Shultz LD; Palucka K; Keck JG
    FASEB J; 2018 Mar; 32(3):1537-1549. PubMed ID: 29146734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models.
    Rosato RR; Dávila-González D; Choi DS; Qian W; Chen W; Kozielski AJ; Wong H; Dave B; Chang JC
    Breast Cancer Res; 2018 Sep; 20(1):108. PubMed ID: 30185216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy.
    Lin S; Huang G; Cheng L; Li Z; Xiao Y; Deng Q; Jiang Y; Li B; Lin S; Wang S; Wu Q; Yao H; Cao S; Li Y; Liu P; Wei W; Pei D; Yao Y; Wen Z; Zhang X; Wu Y; Zhang Z; Cui S; Sun X; Qian X; Li P
    MAbs; 2018; 10(8):1301-1311. PubMed ID: 30204048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor effects of anti-PD-1 antibody, pembrolizumab, in humanized NSG PDX mice xenografted with dedifferentiated liposarcoma.
    Choi B; Lee JS; Kim SJ; Hong D; Park JB; Lee KY
    Cancer Lett; 2020 May; 478():56-69. PubMed ID: 32145342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
    Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
    J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An improved cell line-derived xenograft humanized mouse model for evaluation of PD-1/PD-L1 blocker BMS202-induced immune responses in colorectal cancer.
    Shang P; Yu L; Cao S; Guo C; Zhang W
    Acta Biochim Biophys Sin (Shanghai); 2022 Oct; 54(10):1497-1506. PubMed ID: 36269133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit.
    Wang J; Fei K; Jing H; Wu Z; Wu W; Zhou S; Ni H; Chen B; Xiong Y; Liu Y; Peng B; Yu D; Jiang H; Liu J
    MAbs; 2019; 11(8):1443-1451. PubMed ID: 31402780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models.
    Pyo KH; Kim JH; Lee JM; Kim SE; Cho JS; Lim SM; Cho BC
    Lung Cancer; 2019 Jan; 127():112-121. PubMed ID: 30642538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
    Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
    Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of CXCR5
    Perdomo-Celis F; Medina-Moreno S; Davis H; Bryant J; Taborda NA; Rugeles MT; Kottilil S; Zapata JC
    Immunobiology; 2020 Mar; 225(2):151885. PubMed ID: 31836302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of an Adrenocortical Cancer Humanized Mouse Model to Characterize Anti-PD1 Effects on Tumor Microenvironment.
    Lang J; Capasso A; Jordan KR; French JD; Kar A; Bagby SM; Barbee J; Yacob BW; Head LS; Tompkins KD; Freed BM; Somerset H; Clark TJ; Pitts TM; Messersmith WA; Eckhardt SG; Wierman ME; Leong S; Kiseljak-Vassiliades K
    J Clin Endocrinol Metab; 2020 Jan; 105(1):26-42. PubMed ID: 31513709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human CD141
    Lee YS; O'Brien LJ; Walpole CM; Pearson FE; Leal-Rojas IM; Masterman KA; Atkinson V; Barbour A; Radford KJ
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy.
    Issafras H; Fan S; Tseng CL; Cheng Y; Lin P; Xiao L; Huang YJ; Tu CH; Hsiao YC; Li M; Chen YH; Ho CH; Li O; Wang Y; Chen S; Ji Z; Zhang E; Mao YT; Liu E; Yang S; Jiang W
    PLoS One; 2021; 16(12):e0257972. PubMed ID: 34972111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse.
    Ashizawa T; Iizuka A; Nonomura C; Kondou R; Maeda C; Miyata H; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Katano I; Ito M; Akiyama Y
    Clin Cancer Res; 2017 Jan; 23(1):149-158. PubMed ID: 27458246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoencapsulated rituximab mediates superior cellular immunity against metastatic B-cell lymphoma in a complement competent humanized mouse model.
    Wen J; Wang L; Ren J; Kranz E; Chen S; Wu D; Kanazawa T; Chen I; Lu Y; Kamata M
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4
    Kristensen LK; Fröhlich C; Christensen C; Melander MC; Poulsen TT; Galler GR; Lantto J; Horak ID; Kragh M; Nielsen CH; Kjaer A
    Theranostics; 2019; 9(26):8221-8238. PubMed ID: 31754392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes.
    Marín-Jiménez JA; Capasso A; Lewis MS; Bagby SM; Hartman SJ; Shulman J; Navarro NM; Yu H; Rivard CJ; Wang X; Barkow JC; Geng D; Kar A; Yingst A; Tufa DM; Dolan JT; Blatchford PJ; Freed BM; Torres RM; Davila E; Slansky JE; Pelanda R; Eckhardt SG; Messersmith WA; Diamond JR; Lieu CH; Verneris MR; Wang JH; Kiseljak-Vassiliades K; Pitts TM; Lang J
    Front Immunol; 2021; 12():607282. PubMed ID: 33854497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD8-positive lymphocytes in graft-versus-host disease of humanized NOD.Cg-Prkdc(scid)Il2rg(tm1Wjl)/SzJ mice.
    Laing ST; Griffey SM; Moreno ME; Stoddart CA
    J Comp Pathol; 2015; 152(2-3):238-42. PubMed ID: 25670669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An autologous humanized patient-derived-xenograft platform to evaluate immunotherapy in ovarian cancer.
    Gitto SB; Kim H; Rafail S; Omran DK; Medvedev S; Kinose Y; Rodriguez-Garcia A; Flowers AJ; Xu H; Schwartz LE; Powell DJ; Simpkins F
    Gynecol Oncol; 2020 Jan; 156(1):222-232. PubMed ID: 31818495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment of a patient-derived xenograft model and cell line of malignant transformation of mature cystic teratoma of the ovary.
    Tamauchi S; Suzuki S; Xuboya C; Yoshihara M; Yoshida K; Ikeda Y; Yoshikawa N; Kajiyama H; Kikkawa F
    J Obstet Gynaecol Res; 2021 Feb; 47(2):713-719. PubMed ID: 33300248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.